Literature DB >> 19915981

Diagnostic value of 18F-dihydroxyphenylalanine positron emission tomography for growth hormone-producing pituitary adenoma.

Takafumi Taguchi1, Toshihiro Takao, Yasumasa Iwasaki, Kenichi Oyama, Shozo Yamada, Mari Inoue, Yoshio Terada.   

Abstract

A 55-year-old woman with signs of acromegaly was referred to our hospital. Endocrinological examinations showed that she had high levels of growth hormone (GH; 5.54 ng ml(-1); normal range: 0.66-3.68 ng ml(-1)) and insulin-like growth factor-I (IGF-I; 508 ng ml(-1); normal range: 37-266 ng ml(-1)) levels, incomplete suppression of serum GH following a 75-gram oral glucose tolerance test (oGTT; trough GH 3.66 ng ml(-1)), and paradoxical GH responses to a TRH provocation test (peak GH 38.9 ng ml(-1)). Dynamic magnetic resonance imaging (MRI) suggested the presence of an intrasellar mass lesion (5.9 x 2.8 mm) in the left part of her pituitary gland (Fig. 1a, upper panel). F-18 fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging clearly showed focal but remarkable FDG uptake (Fig. 1a, lower panel), consistent with the localization of the tumor suspected on MRI. The tumor was removed by transsphenoidal surgery. Subsequent histological analysis confirmed the diagnosis of a GH-producing pituitary adenoma. After removal, serum IGF-I levels decreased to a normal range (178 ng ml(-1)), and serum GH was appropriately suppressed during oGTT (trough GH 0.30 ng ml(-1)), suggesting that complete resection was obtained [1]. While postsurgical changes made it difficult to detect any residual lesion on MRI (Fig. 1b, upper panel), abnormal FDG uptake was not seen on FDG-PET after surgery (Fig. 1b, lower panel). PET scans are reported to be a valuable tool for the detection of pituitary adenomas [2-4]. This case clearly showed that FDG-PET is also useful for re-evaluation of the disease after surgery. PET scans are recommended for patients with equivocal pituitary mass lesions on conventional MRI, and for follow-up examinations after surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19915981     DOI: 10.1007/s11102-009-0208-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  4 in total

1.  Positron emission tomography in acromegaly and other pituitary adenoma patients.

Authors:  Carin Muhr
Journal:  Neuroendocrinology       Date:  2006       Impact factor: 4.914

2.  Pituitary microadenomas: a PET study.

Authors:  B De Souza; A Brunetti; M J Fulham; R A Brooks; D DeMichele; P Cook; L Nieman; J L Doppman; E H Oldfield; G Di Chiro
Journal:  Radiology       Date:  1990-10       Impact factor: 11.105

3.  11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas.

Authors:  B N T Tang; M Levivier; M Heureux; D Wikler; N Massager; D Devriendt; P David; N Dumarey; B Corvilain; S Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-15       Impact factor: 9.236

4.  The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.

Authors:  John D Carmichael; Vivien S Bonert; James M Mirocha; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2008-11-25       Impact factor: 5.958

  4 in total
  3 in total

1.  Evolution of (18)FDG pituitary uptake after medical control of acromegaly.

Authors:  Jean-Christophe Maiza; Cedric Revel
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

Review 2.  Metabolic In Vivo Visualization of Pituitary Adenomas: a Systematic Review of Imaging Modalities.

Authors:  Amy Yao; Priti Balchandani; Raj K Shrivastava
Journal:  World Neurosurg       Date:  2017-04-28       Impact factor: 2.104

3.  Positron emission tomography-computed tomography coregistration for diagnosis and intraoperative localization in recurrent nelson syndrome.

Authors:  Eric B Hintz; Jeffery M Tomlin; Vaseem Chengazi; G Edward Vates
Journal:  J Neurol Surg Rep       Date:  2013-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.